Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study
RHEUMATOLOGY AND THERAPY（2024）
关键词
Abatacept,Biologic disease-modifying antirheumatic drug inadequate response (bDMARD-IR),Efficacy,Janus kinase (JAK) inhibitor,Patient-reported outcomes (PROs),Rheumatoid arthritis (RA),Safety,SELECT-CHOICE,Upadacitinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要